Inhibiting MDH2 in glioblastoma stem cells enhanced the effectiveness of dasatinib, a multi-kinase inhibitor, suggesting a potential therapeutic approach for targeting stem-like tumor cells by reprogramming their metabolism (117). The gene discussed is MDH2; the disease is glioblastoma.